[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wecare Probiotics Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":437},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,42,62,82,99,115,134,156,176,197,219,239,261,282,302,321,339,358,376,395,415],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100651834","probiotics-improve-constipation-100651834",false,"NCT07765004","Probiotics Improve Constipation","Safety and Efficacy of Probiotics for Constipation Relief in Adults: A Randonmized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 65 years (inclusive).\n* Diagnosed with constipation, defined as fewer than 3 spontaneous bowel movements per week and\u002For Bristol Stool Form Scale types 1 or 2.\n* Willing and able to comply with the study protocol and complete all required assessments.\n* Provide written informed consent prior to any study-related procedures.\n* Male and female participants of childbearing potential must agree to use effective contraception voluntarily from 14 days prior to screening until 6 months after the end of the trial. Female participants of non-childbearing potential (e.g., post-menopausal or surgically sterile) are exempt from this requirement.\n\nExclusion Criteria:\n\n* Use of products with functions similar to the investigational product within a short period prior to screening that may interfere with the evaluation of study outcomes.\n* Intention to change dietary habits significantly during the study period.\n* Severe allergies or immunodeficiency.\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial.\n* Severe diseases of vital organs (including cardiovascular, pulmonary, hepatic, or renal disease), metabolic diseases (e.g., diabetes, thyroid disorders), malignancy, or severe immune system disorders.\n* Use of antibiotics within the past 30 days.\n* Severe psychological or psychiatric disorders.\n* Poor compliance (e.g., failure to take the test product as instructed or failure to attend scheduled follow-up visits) that would preclude a valid assessment of efficacy.\n* Organic constipation (e.g., caused by structural or pathological conditions).\n* Irritable bowel syndrome with constipation (IBS-C).\n* History of surgical procedures within 30 days prior to screening that may have caused or contributed to constipation symptoms.\n* Intake of probiotic or prebiotic supplements within one month prior to the start of the study.\n* Any other condition that, in the investigator's opinion, would make the participant unsuitable for participation in the study.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},76,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is a randomized, double-blind, placebo-controlled trial in which adult subjects with constipation are randomly assigned to either a probiotic group or a placebo group for an 8-week intervention. Through blood and fecal sample analyses combined with multidimensional questionnaire assessments, the study aims to systematically evaluate the efficacy of probiotics in improving gastrointestinal function, immune status, and mental health in patients with constipation.",[28],"Constipation","RECRUITING","2026-08-13",{"date":32,"type":33},"2026-08-17","ACTUAL",{"date":35,"type":22},"2026-08-07",{"date":37,"type":22},"2026-12-20",{"name":39,"class":40},"Wecare Probiotics Co., Ltd.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":61,"locationsCount":41},"100633651","adults-with-constipation-100633651","NCT07529457","Adults With Constipation","To Evaluate the Efficacy and Safety of Probiotics in Alleviating Constipation in Adults Through a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Men and women aged between 18 and 65 years;\n2. Participants presenting with constipation, characterized by \\\u003C3 spontaneous bowel movements per week or BSFS stool types 1-2;\n3. Capable of following the study protocol and completing all required assessments; Individuals who have voluntarily signed the informed consent form;\n4. No plans for pregnancy from at least 14 days prior to screening through 6 months after the study, with agreement to use reliable contraception methods.\n\nExclusion Criteria:\n\n1. Intake of similar functional products within a short period prior to enrollment that could influence study results;\n2. Participants who significantly alter their habitual diet during the trial;\n3. Individuals with severe allergic conditions or impaired immune function;\n4. Women who are pregnant, lactating, or intending to conceive;\n5. Patients with serious underlying diseases affecting major organs or metabolic systems;\n6. Antibiotic treatment within 2 weeks before enrollment;\n7. Individuals with severe mental or psychological disorders;\n8. Non-compliance with study requirements, including improper intake or missed follow-ups;\n9. Other subjects considered inappropriate for participation by the investigator.",{"count":50,"type":22},70,[25],"This randomized, double-blind, placebo-controlled trial will assess the clinical effects of Akk09 in adults with functional constipation. Participants will receive Akk09 or placebo for 8 weeks. The study will evaluate changes in bowel habits and symptom burden, as well as alterations in host inflammatory status, immune modulation, microbial ecosystem dynamics, neuroendocrine signaling related to the gut-brain axis, and systemic metabolic responses, to characterize the overall physiological impact of Akk09 supplementation.",[28],"NOT_YET_RECRUITING","2026-07-23",{"date":57,"type":33},"2026-07-24",{"date":57,"type":22},{"date":60,"type":22},"2027-05-20",{"name":39,"class":40},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":47,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":68,"targetDuration":4,"studyType":23,"phases":70,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":41},"100631997","probiotics-for-constipation-relief-in-adults-100631997","NCT07507955","Probiotics for Constipation Relief in Adults","Inclusion Criteria:\n\n1. Adults aged 18-65 years;\n2. Individuals diagnosed with constipation, defined as fewer than 3 bowel movements per week and\u002For Bristol Stool Form Scale (BSFS) types 1-2;\n3. Able and willing to comply with all study procedures and complete the study;\n4. Provided written informed consent prior to participation;\n5. Participants (including males) must have no intention of conception from 14 days before screening until 6 months after study completion and agree to use effective contraception.\n\nExclusion Criteria:\n\n1. Recent use of products with similar effects that may interfere with study outcomes; Significant dietary changes during the study period;\n2. History of severe allergy or immunodeficiency;\n3. Pregnant or breastfeeding women, or those planning pregnancy;\n4. Presence of serious systemic diseases (e.g., cardiovascular, pulmonary, hepatic, renal, endocrine, or malignant conditions);\n5. Use of antibiotics within the past 2 weeks;\n6. Individuals with severe psychiatric or neurological disorders;\n7. Poor compliance, including failure to take the study product or attend scheduled visits;\n8. Any other condition deemed unsuitable by the investigator.",{"count":69,"type":22},105,[25],"This study aims to evaluate the efficacy and safety of Bifidobacterium animalis subsp. lactis BLa36 in adults with functional constipation. In this randomized, double-blind, placebo-controlled trial, participants will receive BLa36 supplementation or placebo for 8 weeks. Clinical outcomes will be assessed using validated gastrointestinal symptom scales, stool characteristics, and quality-of-life measures. In addition, changes in inflammatory and immune markers, gut microbiota composition, metabolic indicators, and gut-brain axis-related parameters will be evaluated to comprehensively determine the effects of BLa36 on intestinal function and overall health.",[73],"Functional Constipation","2026-06-05",{"date":76,"type":33},"2026-06-09",{"date":78,"type":22},"2026-06-10",{"date":80,"type":22},"2027-01-20",{"name":39,"class":40},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":47,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100628504","probiotic-intervention-in-constipation-100628504","NCT07462494","Probiotic Intervention in Constipation","Inclusion Criteria:\n\n1. Aged 18-65 years.\n2. Patients with constipation, defined as fewer than three bowel movements per week and\u002For Bristol Stool Form Scale (BSFS) types 1-2.\n3. Able to comply with the study protocol and complete the study procedures.\n4. Participants who have voluntarily signed the informed consent form.\n5. Participants (including male participants) must have no plans for pregnancy from 14 days before screening until 6 months after the end of the study and must agree to use effective contraception during this period.\n\n   \\-\n\nExclusion Criteria:\n\n1. Individuals who have recently taken products with similar functions to the investigational product that may affect the evaluation of study outcomes.\n2. Participants who plan to change their dietary habits during the study period.\n3. Patients with severe allergies or immunodeficiency.\n4. Women who are pregnant, breastfeeding, or planning to become pregnant.\n5. Patients with severe diseases of major organs such as the cardiovascular system, lungs, liver, or kidneys, or those with severe metabolic diseases (e.g., diabetes or thyroid disorders), malignant tumors, or severe immune system diseases.\n6. Individuals who have used antibiotics within the past two weeks.\n7. Individuals with severe psychological or psychiatric disorders.\n8. Participants who fail to take the investigational product as required or fail to attend scheduled follow-up visits, resulting in an inability to determine treatment efficacy.\n9. Any other participants considered unsuitable for participation in the study by the investigator.\n\n   \\-",{"count":89,"type":22},30,[25],"To evaluate the effects of probiotic intervention on gastrointestinal function in patients with constipation after 4 weeks of treatment, and to explore its potential effects on immune status and bone metabolism.",[93],"Gastrointestinal Function",{"date":76,"type":33},{"date":78,"type":22},{"date":97,"type":22},"2026-12-30",{"name":39,"class":40},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":112,"leadSponsor":114,"locationsCount":41},"100628503","probiotic-improve-constipation-100628503","NCT07462481","Probiotic Improve Constipation","A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Probiotics in Relieving Constipation in Adults","Inclusion Criteria:\n\n(1) Age 18-65 years; (2) Constipated patients (less than 3 bowel movements per week and\u002For Bristol Scale type 1 and 2); (3) Able to complete the study according to the trial protocol; (4) Patients who have signed the informed consent form; (5) Study participants (including male study participants) have no plans to have children within 14 days prior to screening and within 6 months after the end of the trial and voluntarily use effective contraception.\n\n\\-\n\nExclusion Criteria:\n\n1. Those who have taken a substance with a similar function to the test subject in a short period of time, affecting their judgment of the results;\n2. Patients who changed their diet during the study;\n3. Patients with severe allergies and immunodeficiency;\n4. Pregnant, breastfeeding, or women planning to become pregnant;\n5. Those with severe diseases of vital organs such as the cardiovascular system, lungs, liver, and kidneys, diabetes, thyroid disease, severe metabolic diseases, malignant tumors, or severe immune system diseases;\n6. Those who have used antibiotics in the past two weeks;\n7. Those with severe psychological or mental illnesses;\n8. Those who did not consume the test sample as required or did not follow up on time, resulting in the inability to determine the efficacy;\n9. Other study participants deemed unsuitable by the researchers. -",{"count":69,"type":22},[25],"To evaluate the efficacy and safety of probiotic as a food supplement in regulating bowel habits in patients with chronic constipation, and to compare it with placebo.",[28],{"date":76,"type":33},{"date":78,"type":22},{"date":113,"type":22},"2027-08-01",{"name":39,"class":40},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":133,"locationsCount":41},"100631995","probiotic-for-weight-management-in-overweight-and-obese-adults-100631995","NCT07507929","Probiotic for Weight Management in Overweight and Obese Adults","Effectiveness and Safety of Inactivated Akkermansia Muciniphila Akk11 (34B) on Weight and Energy Metabolism in Overweight and Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Body mass index (BMI) ≥ 24 kg\u002Fm²;\n2. Able and willing to provide written informed consent;\n3. Willing to comply with the study protocol and required restrictions, including adherence to a low-carbohydrate, energy-restricted diet;\n4. No intention to conceive from 14 days prior to screening until 6 months after study completion, and agreement to use effective contraception during this period\n\nExclusion Criteria:\n\n1. Recent use of products with similar functions to the investigational product that may interfere with study outcomes;\n2. History of psychiatric or neurological disorders, celiac disease, lactose intolerance, or known allergies;\n3. Pregnant or breastfeeding women, or those planning to become pregnant during the study period;\n4. Diagnosis of irritable bowel syndrome (IBS), ulcerative colitis, liver cirrhosis, or diabetes mellitus;\n5. Use of antibiotics within 3 months prior to screening;\n6. Inability to comply with the study protocol, including failure to take the investigational product as required or attend scheduled follow-up visits;\n7. Smoking more than 10 cigarettes per day;\n8. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for the study.",{"count":21,"type":22},[25],"To evaluate the impact of pasteurized Akkermansia muciniphila Akk11 capsules versus placebo on body composition (including body weight, BMI, body fat percentage, waist-to-hip ratio, wrist circumference, visceral fat area, and basal metabolic rate) and serum lipid parameters (TC, LDL-C, HDL-C, and TG) in overweight and obese adults.",[126],"Obesity","2026-03-27",{"date":129,"type":33},"2026-04-02",{"date":131,"type":22},"2026-03-20",{"date":97,"type":22},{"name":39,"class":40},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":41},"100615031","effects-of-bla80-and-lra05-on-the-gut-microbiota-metabolite-profile-of-healthy-individuals-100615031","NCT07287306","Effects of BLa80 and LRa05 on the Gut Microbiota Metabolite Profile of Healthy Individuals","Effects of BLa80 and LRa05 on the Gut Microbiota Metabolite Profile of Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Male or female participants aged 18 to 60 years;\n2. Healthy individuals;\n3. Participants must provide written informed consent.\n\nExclusion Criteria:\n\n1. History of gastrointestinal surgery, other gastrointestinal diseases, metabolic disorders, immunodeficiency, hyperthyroidism, or cardiac or liver disease;\n2. Use of immunosuppressants;\n3. Pregnant or breastfeeding women;\n4. Participants who have taken antibiotics or probiotics within the previous 3 months;\n5. Planned surgery during the study period;\n6. Patients with neurological disorders or psychiatric illness.","60 Years",{"count":143,"type":22},375,[25],"Gut microbiota play a key role in polyphenol metabolism, participating in the breakdown of dietary components and producing various small molecule metabolites that affect human health. However, little is currently known about how gut microbes metabolize dietary compounds and produce bioactive metabolites. This study aims to use metabolomics to precisely identify food-derived metabolites in the blood to investigate whether probiotics (BLa80, LRa05) can enhance the breakdown of dietary components and improve their absorption and utilization in the human body.",[147],"Healthy Individuals","2025-12-16",{"date":150,"type":33},"2025-12-17",{"date":152,"type":33},"2025-12-10",{"date":154,"type":22},"2026-11-15",{"name":39,"class":40},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":41},"100599177","probiotics-and-non-organic-gastrointestinal-improvement-100599177","NCT07081100","Probiotics and Non-Organic Gastrointestinal Improvement","Study on the Effect of Probiotics on Improving Gastrointestinal Function in Patients With Non-organic Gastrointestinal Dysfunction","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form and agree to participate in the study.\n* Ability to complete the study according to the trial protocol requirements.\n* Aged 18-65 years.\n* Clinical diagnosis of non-organic gastrointestinal dysfunction (e.g., functional dyspepsia, functional constipation) without other serious organic diseases.\n\nExclusion Criteria:\n\n* Use of drugs affecting intestinal flora (antibiotics, probiotics, intestinal mucosal protectants, herbal medicines, etc.) for \\>1 week within 1 month prior to screening.\n* Short-term use of products with functions similar to the investigational product, which may interfere with result interpretation.\n* Antibiotic use during the study period.\n* History of severe systemic diseases or malignancies.\n* Allergy to any ingredient in the compound probiotic freeze-dried powder used in the trial.\n* Pregnancy, lactation, or plans for pregnancy in the near future.\n* Inability to participate due to personal reasons.\n* Other conditions deemed unsuitable by the investigators.",{"count":164,"type":22},50,[25],"To verify the improvement of gastrointestinal function in patients with non-organic gastrointestinal dysfunction after 4 weeks of intervention with compound probiotics.",[93],"2025-07-28",{"date":170,"type":33},"2025-07-31",{"date":172,"type":22},"2025-08-05",{"date":174,"type":22},"2026-03-01",{"name":39,"class":40},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":41},"100572041","safety-and-tolerability-evaluation-of-akkermansia-muciniphila-100572041","NCT06728098","Safety and Tolerability Evaluation of Akkermansia Muciniphila","Safety and Tolerability Evaluation of Heat-Inactivated Akkermansia Muciniphila Akk11: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n1. Male or Female subject age 18-60 years at screening.\n2. Healthy subject according to investigator judgement based on screening data.\n3. Subjects must be either of non-childbearing potential, or if of childbearing potential, they must be abstinent or have practiced adequate contraception for the entire study.\n4. Subjects who have not smoked in the past 1 month prior to screening.\n5. Subjects with a healthy and balanced diet, including adequate fiber intake in their food consumption.\n6. Subject or subject's legally acceptable representatives have the ability to comply with the trial protocol.\n7. Signed informed consent from the subject or subject's legally acceptable representatives (must be obtained before any trial related activities).\n\nExclusion Criteria:\n\n1. History of or presence of diabetes, immunodeficiency disorders, or chronic illness.\n2. Regular use of medications known to affect the gastrointestinal system or alter gut microbiota composition, including but not limited to antibiotics, and immunosuppressants.\n3. Have continuous, daily use of probiotics or probiotic containing products within 1 month prior to randomization.\n4. Pregnant, planning a pregnancy or lactating female (urinary pregnancy test will be applied to female subjects at screening).\n5. Change type of diet during study.\n6. Any known allergy or intolerance to any of the ingredients in the formulation of the product under study.\n7. History of drug, alcohol or other substance abuse, or other factors that limit their ability to cooperate during the study.\n8. History of or presence of eating disorder.\n9. Subject whose condition does not make them eligible to the study, according to the investigator.",{"count":184,"type":22},108,[25],"This is a randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of Akkermansia muciniphila Akk11 in healthy adult.",[188],"Healthy","2025-07-24",{"date":191,"type":33},"2025-07-29",{"date":193,"type":22},"2025-11-25",{"date":195,"type":22},"2026-03-25",{"name":39,"class":40},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":16,"sex":204,"minAge":18,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":218,"locationsCount":41},"100591965","lactobacillus-plantarum-and-hormonal-regulation-in-obese-women-100591965","NCT06987279","Lactobacillus Plantarum and Hormonal Regulation in Obese Women","Lactobacillus Plantarum Lp90 and Hormonal Regulation in Obese Women：A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Age: 18 to 40 years old, female, BMI ≥ 25 kg\u002Fm2.\n2. Be willing to receive follow-up during the intervention period.\n3. Be willing to provide two blood, urine and fecal samples during the intervention period.\n4. Be willing to take the compound probiotics by oneself every day during the intervention period.\n5. Have good hearing and be able to hear and understand all instructions during the intervention period.\n\n   \\-\n\nExclusion Criteria:\n\n1. Suffering from digestive system diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease).\n2. Suffering from severe neurological disorders (epilepsy, stroke, severe head trauma, meningitis within the past 10 years, brain surgery, brain tumor, long-term coma - excluding general anesthesia).\n3. Have received\u002Fare currently receiving treatment for the following mental illnesses: alcohol\u002Fdrug\u002Fsubstance abuse dependence, schizophrenia, psychosis, bipolar disorder.\n4. Take medication for depression or low mood.\n5. Suffering from internal organ failure (such as heart, liver or kidney failure, etc.).\n6. Have received radiotherapy or chemotherapy in the past.\n7. Have received general anesthesia surgery\u002Fprocedures within the past three years, or plan to receive general anesthesia procedures\u002Fsurgeries within the next three months during this trial.\n8. Have suffered from hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past.\n\n   \\-","FEMALE","40 Years",{"count":207,"type":22},100,[25],"To evaluate the regulatory effect of Lactobacillus plantans Lp90 formula on visceral fat metabolism and sex hormone balance in obese women.",[211],"Obesity, Women","2025-05-15",{"date":214,"type":33},"2025-05-23",{"date":216,"type":22},"2025-06-10",{"date":152,"type":22},{"name":39,"class":40},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":41},"100576171","research-on-the-use-of-probiotics-in-the-prevention-and-treatment-of-inflammatory-bowel-disease-100576171","NCT06781827","Research on the Use of Probiotics in the Prevention and Treatment of Inflammatory Bowel Disease","Application Research of Lactobacillus Reuteri in the Treatment of Inflammatory Bowel","Inclusion Criteria:\n\n1. Be over 18 years old\n2. Agree to sign informed consent; Have been diagnosed with IBD for at least 3 months but not more than 3 years -\n\nExclusion Criteria:\n\n1. Does not meet the diagnostic criteria of CD\n2. Patients with other autoimmune diseases, infectious diseases and malignant tumors Patients with CD during pregnancy and lactation; Patients with serious diseases of the liver, kidney, heart and lung, etc\n3. Patients with allergic diseases such as asthma and allergic rhinitis; alcoholic Patients with mental illness\n4. Patients with suspected cancer in their intestines\n5. Antibiotics, probiotics and prebiotics have been used in the past three months Had intestinal surgery (except appendicitis surgery)\n6. There is currently an infection\n7. He has had cancer in the last 5 years -",{"count":164,"type":22},[25],"This project involves the use of oral Lactobacillus reuteri as an adjunct therapy for 8 weeks. Endoscopic observation of intestinal inflammation will be conducted at 1 month, 3 months, 6 months, and 12 months after the administration of the drug. Intestinal fluid will be collected endoscopically for 16S RNA analysis to assess changes in the gut microbiota. Inflammatory changes in the patients will be detected through peripheral blood tests, and fecal calprotectin levels will be measured to evaluate the progression of the disease.",[230],"Inflammatory Bowel Disease","2025-03-31",{"date":233,"type":33},"2025-04-04",{"date":235,"type":33},"2025-01-01",{"date":237,"type":22},"2025-12-30",{"name":39,"class":40},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":41},"100585394","efficacy-of-lactobacillus-rhamnosus-lra05-in-gestational-diabetes-100585394","NCT06901791","Efficacy of Lactobacillus Rhamnosus LRa05 in Gestational Diabetes","Assessing the Efficacy of Lactobacillus Rhamnosus LRa05 in Improving Blood Glucose and Gut Microbiota in Patients With Gestational Diabetes","Inclusion Criteria:\n\n1. Women diagnosed with gestational diabetes mellitus (GDM) at 24 weeks of gestation.\n\n   Diagnostic criteria for GDM: Abnormal oral glucose tolerance test (OGTT) with an 82.5g glucose load during the 24th week of pregnancy (defined as meeting one or more of the following plasma glucose thresholds: fasting ≥ 5.1 mmol\u002FL, 1-hour ≥ 10 mmol\u002FL, or 2-hour ≥ 8.5 mmol\u002FL).\n2. Pregnant women aged 18 to 50 years.\n3. Singleton pregnancy with a fetus confirmed to be structurally and chromosomally normal via ultrasound or other prenatal diagnostic methods.\n4. No history of chronic diseases, including immune deficiency, hypertension, diabetes, kidney disease, or liver disease.\n5. No consumption of probiotic-containing foods (e.g., yogurt, fermented foods, soybean paste) within the two weeks prior to the study.\n6. Willing and able to provide written informed consent.\n7. Capable of complying with the study protocol and follow-up requirements.\n\nExclusion Criteria:\n\n1. Those who have taken items with similar functions to the test product in the short term, which may affect the judgment of the results.\n2. Those with other endocrine diseases or currently using medications that affect blood glucose control.\n3. Those with severe cardiovascular, kidney, or liver diseases.\n4. Those with immunodeficiency diseases or currently using immunosuppressive agents.\n5. Those with severe gastrointestinal diseases that may affect the absorption or metabolism of probiotics.\n6. Those currently using other medications that may affect blood glucose control or lipid levels.\n7. Those with a history of allergy to probiotics or any components of the study products.\n8. Those with unhealthy lifestyle habits, such as smoking, alcohol consumption, or drug abuse.\n9. Those who do not consume the test samples as required or do not follow up on time, resulting in uncertain efficacy.\n10. Study participants deemed unsuitable by other researchers.","50 Years",{"count":248,"type":22},80,[25],"This study aims to comprehensively evaluate the multifaceted impacts of Lactobacillus rhamnosus LRa05 on patients with gestational diabetes. Initially, the study will investigate the effects of LRa05 on improving patients' blood glucose levels and gut microbiota. Additionally, the study will assess the impact of this strain on patients' blood lipid levels, inflammatory markers, and body mass index (BMI). Furthermore, the study will also focus on its effects on thyroid function, vaginal microbiota, and bile acid metabolism in patients with gestational diabetes.",[252],"GDM","2025-03-28",{"date":255,"type":33},"2025-03-30",{"date":257,"type":22},"2025-04-10",{"date":259,"type":22},"2026-03-10",{"name":39,"class":40},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":281,"locationsCount":41},"100584237","investigating-the-efficacy-of-probiotics-in-enhancing-gastrointestinal-and-immunological-health-100584237","NCT06886724","Investigating the Efficacy of Probiotics in Enhancing Gastrointestinal and Immunological Health","A Study on the Role of Ligilactobacillus Salivarius LS97 in Modulating Gut Microbiota and Immune System Function","Inclusion Criteria:\n\n1. Willing to undergo 3 follow-up visits during the intervention period\n2. Be willing to provide blood, urine and stool samples 2 times during the intervention period\n3. Good eyesight, can read and write, can wear glasses\n4. Have good hearing and be able to hear and understand all instructions during the intervention\n\nExclusion Criteria:\n\n1. Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)\n2. Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor prolonged coma - not including general anaesthesia)\n3. Have received\u002Fare receiving treatment for the following mental disorders: alcohol\u002Fdrug\u002Fsubstance abuse dependence, schizophrenia psychosis, bipolar disorder\n4. Take medication for depression or low mood\n5. Internal organ failure (heart, liver or kidney failure, etc.)\n6. Have received radiation or chemotherapy in the past\n7. have undergone a general anesthesia procedure\u002Fprocedure within the past three years, or plan to undergo a general anesthesia procedure\u002Fprocedure within the next 3 months during this trial period\n8. Have had hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past","45 Years",{"count":270,"type":22},40,[25],"Evaluate the effectiveness and safety of Ligilactobacillus salivarius LS97 as a food supplement compared to a placebo in improving intestinal and immune functions in healthy adults.",[274],"Intestinal and Lmmune Function Lmproved","2025-03-13",{"date":277,"type":33},"2025-03-20",{"date":279,"type":22},"2025-03-10",{"date":237,"type":22},{"name":39,"class":40},{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":268,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":300,"leadSponsor":301,"locationsCount":41},"100584236","research-on-the-role-of-probiotics-in-human-intestinal-health-100584236","NCT06886711","Research on the Role of Probiotics in Human Intestinal Health","A Study on the Safety and Efectiveness of Bifidobacterium Bifidum BBi32 in Improving Lntestinal and Lmmune Functions","Inclusion Criteria:\n\n1. Willing to attend 3 follow-up visits during the intervention period\n2. Agree to provide blood, urine, and stool samples twice during the intervention period\n3. Good eyesight, able to read and write, and capable of wearing glasses if needed\n4. Good hearing and able to fully comprehend all instructions during the intervention\n\nExclusion Criteria:\n\n1. Presence of digestive diseases, particularly gastrointestinal disorders (e.g., celiac disease, ulcerative colitis, Crohn's disease)\n2. History of serious neurological conditions (e.g., epilepsy, stroke, severe head trauma, meningitis within the last 10 years, brain surgery, brain tumor, or prolonged coma-not including general anesthesia)\n3. History of or currently receiving treatment for mental health disorders such as alcohol\u002Fdrug\u002Fsubstance abuse, schizophrenia, psychosis, or bipolar disorder\n4. Currently taking medication for depression or low mood\n5. Presence of internal organ failure (e.g., heart, liver, or kidney failure)\n6. History of radiation therapy or chemotherapy treatments\n7. Underwent general anesthesia within the past three years or are scheduled for general anesthesia within the next 3 months during the trial period\n8. History of hepatitis (B or C), HIV, or syphilis",{"count":290,"type":22},45,[25],"Evaluate the efectiveness and safety of Bifidobacterium bifidum BBi32 as a food supplement compared to a placebo in improving intestinal andimmune functions in healthy adults.",[294],"Intestinal Microbiota",[296,297],"Probiotics","Intestinal Barrier Function",{"date":277,"type":33},{"date":279,"type":22},{"date":237,"type":22},{"name":39,"class":40},{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":268,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":310,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":4},"100583365","the-role-of-probiotic-lh76-in-human-gut-health-100583365","NCT06875375","The Role of Probiotic LH76 in Human Gut Health","A Clinical Study on the Safety and Efficacy of Probiotic LH76 in Modulating Gut Microbiota and Enhancing Intestinal Health in Healthy Adults","Inclusion Criteria:\n\n1. Willing to undergo 3 follow-up visits during the intervention period Be willing to provide blood, urine and stool samples 2 times during the intervention period\n2. Willing to self-administer probiotic or placebo once a day during the intervention period\n3. Good eyesight, can read and write, can wear glasses\n4. Have good hearing and be able to hear and understand all instructions during the intervention\n\nExclusion Criteria:\n\n1. Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)\n2. Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor, prolonged coma - not including general anaesthesia)\n3. Have received\u002Fare receiving treatment for the following mental disorders: alcohol\u002Fdrug\u002Fsubstance abuse dependence, schizophrenia, psychosis, bipolar disorder\n4. Take medication for depression or low mood Internal organ failure (heart, liver or kidney failure, etc.)\n5. Have received radiation or chemotherapy in the past\n6. Have undergone a general anesthesia procedure\u002Fprocedure within the past three years, or plan to undergo a general anesthesia procedure\u002Fprocedure within the next 3 months during this trial period\n7. Have had hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past Open Contacts\u002FLocations",{"count":164,"type":22},[25],"This study aims to evaluate the safety and efficacy of the probiotic LH76 as a dietary supplement in healthy adults. The research will assess its effects on gut microbiota composition, intestinal health, and immune function compared to a placebo. Key outcomes include changes in microbial diversity, intestinal barrier integrity, and immune response markers over the intervention period. The findings will contribute to understanding the potential health benefits of LH76 and its role in supporting gut and immune health.",[313],"Gut Microbiota Modulation",{"date":315,"type":33},"2025-03-18",{"date":317,"type":22},"2025-05-11",{"date":319,"type":22},"2025-10-26",{"name":39,"class":40},{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":268,"enrollmentInfo":328,"targetDuration":4,"studyType":23,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":337,"leadSponsor":338,"locationsCount":41},"100583215","research-on-the-improvement-of-intestinal-and-immune-functions-by-probiotics-100583215","NCT06873425","Research on the Improvement of Intestinal and Immune Functions by Probiotics","A Study on the Safety and Effectiveness of Limosilactobacillus Fermentum LF61 in Improving Intestinal and Immune Functions","Inclusion Criteria:\n\n1. Willing to undergo 3 follow-up visits during the intervention period\n2. Be willing to provide blood, urine and stool samples 2 times during the intervention period\n3. Willing to self-administer one of the 7 probiotics (BI45, BBi32, LS97, LB42, LF61, LH76, LR08)\u002Fplacebo once a day during the intervention period\n4. Good eyesight, can read and write, can wear glasses\n5. Have good hearing and be able to hear and understand all instructions during the intervention -\n\nExclusion Criteria:\n\n1. Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)\n2. Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor, prolonged coma - not including general anaesthesia)\n3. Have received\u002Fare receiving treatment for the following mental disorders: alcohol\u002Fdrug\u002Fsubstance abuse dependence, schizophrenia, psychosis, bipolar disorder\n4. Take medication for depression or low mood\n5. Internal organ failure (heart, liver or kidney failure, etc.)\n6. Have received radiation or chemotherapy in the past\n7. have undergone a general anesthesia procedure\u002Fprocedure within the past three years, or plan to undergo a general anesthesia procedure\u002Fprocedure within the next 3 months during this trial period\n8. Have had hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past -",{"count":270,"type":22},[25],"Evaluate the effectiveness and safety of Limosilactobacillus fermentum LF61 as a food supplement compared to a placebo in improving intestinal and immune functions in healthy adults.",[332],"Intestinal Health","2025-03-06",{"date":335,"type":33},"2025-03-12",{"date":279,"type":22},{"date":237,"type":22},{"name":39,"class":40},{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":17,"minAge":205,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":355,"leadSponsor":357,"locationsCount":4},"100583214","effects-of-compound-probiotics-polygonatum-sibiricum-on-liver-health-and-metabolism-in-middle-aged-and-elderly-people-100583214","NCT06873412","Effects of Compound Probiotics-Polygonatum Sibiricum on Liver Health and Metabolism in Middle-aged and Elderly People","The Regulatory Effect of Probiotics-Polygonatum Sibiricum on Liver Health and Metabolic Disorders in Middle-Aged and Elderly People: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n1\\. The age of the subjects is 40-80 years old; 2. The subject meets one of the following metabolic disease components: ① abdominal B - ultrasound shows fatty liver or fat infiltration; ② arterial blood pressure is higher than 130\u002F85mmHg, or the subject is on antihypertensive treatment; ③ prediabetes or type 2 diabetes, with fasting blood glucose above 6.1mmol\u002FL; ④ overweight or obesity, with BMI of 24.0kg\u002Fm² or more, or male waist circumference of 90cm or more, female waist circumference of 85cm or more, or excessive body fat content and percentage.\n\n\\-\n\nExclusion Criteria:\n\n1. People who are allergic to any of the pharmaceutical ingredients used in this study; A history of alcohol abuse (drinking more than 14 units of alcohol per week :1 unit = 285mL for beer, 25mL for spirits, 100mL for wine);\n2. Patients who received probiotics within 1 month before taking the experimental drug;\n3. Recent history of gastrointestinal bleeding, obstruction, perforation, tumor and other serious organic diseases;\n4. Aminotransferase index \\> 3 times the normal value;\n5. Kidney disease (creatinine index higher than normal);\n6. Patients with serious psychological and mental diseases, resulting in the inability to express themselves normally;\n7. Patients with infectious liver diseases, such as hepatitis B and C;\n8. The female subject is breastfeeding or has a positive pregnancy test result during the screening period or during the test -","80 Years",{"count":348,"type":22},84,[25],"The purpose of this study was to evaluate the regulatory effects of Huangqian-biobacteria compound preparation on liver health and related metabolic disorders in middle-aged and elderly people, observe its effects on liver function indexes, basal metabolic rate, markers of oxidative stress, inflammatory factors and intestinal microecology, and evaluate the incidence of adverse reactions in subjects during the 3-month intervention period.",[352],"Fatty Liver",{"date":335,"type":33},{"date":279,"type":22},{"date":356,"type":22},"2026-12-01",{"name":39,"class":40},{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":268,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":41},"100582446","study-on-the-enhancement-of-intestinal-and-immune-functions-through-probiotic-intervention-100582446","NCT06863415","Study on the Enhancement of Intestinal and Immune Functions Through Probiotic Intervention","A Study on the Safety and Effectiveness of Bifidobacterium Longum Subsp. infantisBI45 in Improving Intestinal and Immune Functions","Inclusion Criteria:\n\n1. Willing to undergo 3 follow-up visits during the intervention period Be willing to provide blood, urine and stool samples 2 times during the intervention period\n2. Willing to self-administer probiotic or placebo once a day during the intervention period\n3. Good eyesight, can read and write, can wear glasses\n4. Have good hearing and be able to hear and understand all instructions during the intervention\n\nExclusion Criteria:\n\n1. Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)\n2. Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor, prolonged coma - not including general anaesthesia)\n3. Have received\u002Fare receiving treatment for the following mental disorders: alcohol\u002Fdrug\u002Fsubstance abuse dependence, schizophrenia, psychosis, bipolar disorder\n4. Take medication for depression or low mood Internal organ failure (heart, liver or kidney failure, etc.)\n5. Have received radiation or chemotherapy in the past\n6. Have undergone a general anesthesia procedure\u002Fprocedure within the past three years, or plan to undergo a general anesthesia procedure\u002Fprocedure within the next 3 months during this trial period\n7. Have had hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past",{"count":366,"type":22},90,[25],"Evaluate the effectiveness and safety of Bifidobacterium longum subsp. infantis BI45 as a food supplement compared to a placebo in improving intestinal and immune functions in healthy adults.",[188],{"date":279,"type":33},{"date":372,"type":22},"2025-03-15",{"date":374,"type":22},"2025-12-25",{"name":39,"class":40},{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":394,"locationsCount":41},"100581254","exploring-the-potential-benefits-of-probiotic-yogurt-100581254","NCT06847919","Exploring the Potential Benefits of Probiotic Yogurt","Exploring the Potential Benefits of High-activity Probiotic Yogurt: a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Meet the Rome IV diagnosis criteria for chronic constipation;\n2. Patients who are able to understand clinical studies and are committed to complying with study requirements and procedures;\n3. Age 18-65. -\n\nExclusion Criteria:\n\n1. Systemic (diabetes, autoimmune diseases, cancer), gastrointestinal or liver diseases known to be associated with alterations in the gut microbiota;\n2. Patients who are pregnant or lactating;\n3. have taken antimicrobials, probiotics, or drugs that inhibit stomach acid or gastrointestinal motility in the past 6 weeks;\n4. Patients who changed their diet type during the study;\n5. Patients who are allergic or intolerant to any component of the investigational product formulation;\n6. Patients with cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and other serious diseases and endocrine diseases, mental patients;\n7. Stop taking the tested sample or add other drugs in the middle, unable to judge the efficacy or incomplete data;\n8. short-term use of objects related to the function of the test, affecting the judgment of the result;\n9. have been dieting, exercising excessively, taking weight loss medications or taking medications that may affect appetite in the past 3 months;\n10. Current or past excessive use of alcohol, drugs, or supplements that may cause intestinal dysfunction or interfere with the evaluation of the efficacy of the study product -",{"count":348,"type":22},[25],"This study aims to evaluate the effect of a high-activity probiotic yogurt on improving symptoms of chronic constipation, observing its regulatory effects on the gut microbiota and the incidence of adverse reactions in study participants over a 21-day intervention period.",[387],"Chronic Constipation","2025-03-02",{"date":390,"type":33},"2025-03-05",{"date":392,"type":22},"2025-02-25",{"date":237,"type":22},{"name":39,"class":40},{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":16,"sex":204,"minAge":18,"maxAge":19,"enrollmentInfo":402,"targetDuration":4,"studyType":23,"phases":404,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":412,"leadSponsor":414,"locationsCount":4},"100579245","effects-of-lacticaseibacillus-rhamnosus-lra05-on-bacterial-vaginosis-and-ovarian-function-in-women-100579245","NCT06821789","Effects of Lacticaseibacillus Rhamnosus LRa05 on Bacterial Vaginosis and Ovarian Function in Women","Effects of Lacticaseibacillus Rhamnosus LRa05 on Bacterial Vaginosis and Ovarian Function in Women: a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. 18 to 65 years old, sexual activity, premenopausal women;\n2. Nugent score for diagnosing BV ≥7;\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Mixed vaginitis, such as vulvovaginal candidiasis (VVC), Trichomonas vaginalis (TV) infection, Chlamydia trachomatis (CT) infection or gonococcal vaginitis;\n2. history of systemic organic disease or psychiatric illness;\n3. Planning pregnancy, breastfeeding, menstruation;\n4. within 5 days of the onset of the disease, any antibiotics have been used;\n5. long-term use of contraceptives or immunosuppressants;\n6. Allergic constitution or hypersensitivity to known components of the study drug.",{"count":403,"type":22},60,[25],"In this study, Lacticaseibacillus rhamnosus LRa05 was selected as test preparations to observe the clinical efficacy in the intervention trial of combined antibiotic therapy, and to evaluate its effects on the cure rate, recurrence rate and vaginal microbiota of patients with bacterial vaginitis.",[407],"Patients With Bacterial Vaginosis","2025-02-14",{"date":410,"type":33},"2025-02-19",{"date":372,"type":22},{"date":413,"type":22},"2026-05-30",{"name":39,"class":40},{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":16,"sex":17,"minAge":422,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":23,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":41},"100569845","lacticaseibacillus-rhamnosus-lra05-for-alleviating-allergic-rhinitis-in-children-100569845","NCT06699537","Lacticaseibacillus Rhamnosus LRa05 for Alleviating Allergic Rhinitis in Children","Effectiveness of Lacticaseibacillus Rhamnosus LRa05 in Alleviating Allergic Rhinitis and Its Impact on Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Voluntarily, in writing, sign the informed consent form, agreeing to participate in this study;\n2. Capable of completing the study according to the test protocol requirements;\n3. Age between 4 to 12 years old;\n4. Meet the diagnostic criteria for allergic rhinitis established in the \"Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (Revised Edition 2022)\";\n5. Symptoms: Presence of two or more symptoms such as sneezing, watery rhinorrhea, nasal itching, and nasal congestion, with symptoms lasting or accumulating for more than one hour per day, possibly accompanied by eye itching, tearing, and redness, and other ocular symptoms;\n6. Signs: Nasal mucosa is pale and edematous, possibly with watery secretions;\n7. Laboratory tests: At least one allergen detected by skin prick test and\u002For specific IgE positivity in serum;\n8. No use of antihistamines, corticosteroids, or immunosuppressants in the month before screening;\n9. No history of heart, liver, kidney, nervous system, mental disorders, or metabolic abnormalities.\n\nExclusion Criteria:\n\n1. Use of medications affecting the gut microbiota (including antimicrobial drugs, probiotics, intestinal mucosal protective agents, traditional Chinese patent medicines, etc.) for more than 1 week within 1 month prior to screening;\n2. Patients with coexisting pulmonary tuberculosis;\n3. Those with coexisting allergic asthma;\n4. Individuals with nasal polyps or severe nasal septal deviation;\n5. Patients with severe systemic diseases or malignant tumors;\n6. Those with congenital genetic diseases or congenital immunodeficiency diseases;\n7. Regular use of probiotics or prebiotics within 6 months prior to the screening period;\n8. Individuals with severe gastrointestinal diseases (including severe diarrhea, inflammatory bowel diseases, etc.);\n9. Those with metabolic syndrome (including obesity, dyslipidemia, hypertension, diabetes, etc.);\n10. Individuals with sinusitis, otitis media, or respiratory tract infections;\n11. Those allergic to any components of the probiotics used in this trial;\n12. Women who are pregnant or breastfeeding, or those planning to conceive in the near future;\n13. Subjects who discontinue the test sample or add other medications midway, making it impossible to determine efficacy or with incomplete information;\n14. Those who have recently consumed items similar to the test product, affecting the judgment of the results;\n15. Subjects who, due to their own reasons, cannot participate in the trial;\n16. Any other subjects deemed unsuitable to participate by the investigators.","4 Years","12 Years",{"count":50,"type":22},[25],"The clinical trial aims to investigate the efficacy of Lactobacillus rhamnosus LRa05 in alleviating allergic rhinitis and its impact on the gut microbiota among 70 pediatric participants aged 4-12. The primary objective is to validate the improvement in allergic rhinitis symptoms following an 8-week intervention with Lactobacillus rhamnosus LRa05. Participants were instructed to consume the probiotic powder daily for approximately 8 weeks. At baseline, week 4, and week 8 endpoints, assessments of nasal symptoms, quality of life questionnaires, and stool samples for microbiota analysis were conducted on the participants, and blood samples were collected for immune-related factor testing.",[428],"Allergic Rhinitis (AR)","2024-11-20",{"date":431,"type":33},"2024-11-21",{"date":433,"type":22},"2024-12-01",{"date":435,"type":22},"2025-12-01",{"name":39,"class":40},""]